Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Study of Upifitamab rilsodotin + Carboplatin in patients with high grade serous ovarian cancer

An Open-label, Multicenter, Dose Escalation and Expansion Study of upifitamab rilsodotin in combination with carboplatin In Participants with High-grade Serous Ovarian Cancer: A modular study related to upgrade Umbrella Master study

Disease Types: Ovarian

Available at: Roanoke

An Open-label, Multicenter, Dose Escalation and Expansion Study of upifitamab rilsodotin in combination with carboplatin In Participants with High-grade Serous Ovarian Cancer: A modular study related to upgrade Umbrella Master study

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04907968?term=NCT04907968&draw=2&rank=1